Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
暂无分享,去创建一个
A. Alencar | A. Zelenetz | I. Flinn | F. Hernandez-Ilizaliturri | R. Walgren | C. Tam | K. Izutsu | B. Nair | C. Cheah | H. Nagai | A. Mato | Yucai Wang | J. Seymour | M. Balbas | Anita Kumar | C. Ujjani | E. Lech-Maranda | W. Jurczak | Chunxiao Wang | T. Eyre | N. Shah | T. Fenske | K. Maddocks | N. Lamanna | J. Rhodes | P. Abada | J. Gerson | B. Tessoulin | K. Patel | D. Lewis | D. E. Tsai | Michael L. Wang | Shuo Ma | Junjie Zhao | Y. Koh | P. Zinzani | Talha Munir
[1] A. Alencar,et al. Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study , 2022, Blood.
[2] A. Ruppert,et al. BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naïve mantle cell lymphoma. , 2022, Future oncology.
[3] F. Seymour,et al. Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Outcomes in the United Kingdom , 2022, Blood.
[4] E. Giné,et al. Real‐world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR‐2 retrospective chart review study , 2022, British journal of haematology.
[5] M. Tajimi,et al. Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database , 2022, Advances in Therapy.
[6] E. Thompson,et al. Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors , 2021, Blood advances.
[7] L. Staudt,et al. Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. , 2021, Blood cancer discovery.
[8] J. Byrd,et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Michael L. Wang,et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. , 2021, Blood advances.
[10] Michael L. Wang,et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study , 2021, The Lancet.
[11] J. Byrd,et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial , 2020, The Lancet.
[12] Michael L. Wang,et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. , 2020, The New England journal of medicine.
[13] Michael L. Wang,et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma , 2019, Leukemia.
[14] M. Bar,et al. Utilization of Chimeric Antigen Receptor (CAR) T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B cell non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[15] L. Sehn,et al. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. , 2019, Current oncology.
[16] Michael L. Wang,et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis , 2018, Haematologica.
[17] M. Dyer,et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy , 2018, Haematologica.
[18] Michael L. Wang,et al. Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib , 2018, British journal of haematology.
[19] A. Silva,et al. Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All. , 2018, Trends in cancer.
[20] P. Hari,et al. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” study , 2017, Hematological oncology.
[21] M. Dreyling,et al. Bruton’s tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives , 2017, Expert opinion on investigational drugs.
[22] R. V. Van Heertum,et al. Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials , 2017, Drug design, development and therapy.
[23] Larissa V Furtado,et al. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL , 2016, Oncotarget.
[24] R. Advani,et al. Postibrutinib outcomes in patients with mantle cell lymphoma. , 2016, Blood.
[25] D. Chihara,et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] J. Drach,et al. Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial , 2015, British journal of haematology.
[27] Bruce D Cheson,et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] O. Elemento,et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. , 2014, Cancer discovery.
[29] Sonali M. Smith,et al. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. , 2009, Seminars in oncology.
[30] J. Leonard,et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] W. Klapper,et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network , 2005, British journal of haematology.